Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma
AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the Phase III AB08026

Read the full 378 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE